var data={"title":"Pseudomonas aeruginosa pneumonia","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pseudomonas aeruginosa pneumonia</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/contributors\" class=\"contributor contributor_credentials\">Souha S Kanj, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/contributors\" class=\"contributor contributor_credentials\">Daniel J Sexton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/contributors\" class=\"contributor contributor_credentials\">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/contributors\" class=\"contributor contributor_credentials\">Allyson Bloom, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 14, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Pseudomonas aeruginosa</em> is one of the most important and most commonly considered pathogens in the differential diagnosis of gram-negative infections. Consideration of this organism is important because it causes severe hospital-acquired infections, especially in immunocompromised hosts, is often antibiotic resistant, complicating the choice of therapy, and is associated with a high mortality rate.</p><p>The clinical manifestations, diagnosis, and treatment of <em>P. aeruginosa</em> pneumonia will be reviewed here. </p><p>The general principles of antimicrobial treatment of infections caused by <em>P. aeruginosa</em>, including antibiotic options and decisions on combination therapy, are discussed in detail elsewhere. (See <a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections\" class=\"medical medical_review\">&quot;Principles of antimicrobial therapy of Pseudomonas aeruginosa infections&quot;</a>.)</p><p>The clinical manifestations and management of other <em>P. aeruginosa</em> infections and the epidemiology and pathogenesis of infection with this organism are also discussed separately.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection\" class=\"medical medical_review\">&quot;Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pseudomonas-aeruginosa-bacteremia-and-endocarditis\" class=\"medical medical_review\">&quot;Pseudomonas aeruginosa bacteremia and endocarditis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pseudomonas-aeruginosa-skin-and-soft-tissue-infections\" class=\"medical medical_review\">&quot;Pseudomonas aeruginosa skin and soft tissue infections&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pseudomonas-aeruginosa-infections-of-the-eye-ear-urinary-tract-gastrointestinal-tract-and-central-nervous-system\" class=\"medical medical_review\">&quot;Pseudomonas aeruginosa infections of the eye, ear, urinary tract, gastrointestinal tract, and central nervous system&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=cystic-fibrosis-antibiotic-therapy-for-chronic-pulmonary-infection#H2457284300\" class=\"medical medical_review\">&quot;Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection&quot;, section on 'Pseudomonas aeruginosa'</a> and <a href=\"topic.htm?path=cystic-fibrosis-treatment-of-acute-pulmonary-exacerbations#H1513954250\" class=\"medical medical_review\">&quot;Cystic fibrosis: Treatment of acute pulmonary exacerbations&quot;, section on 'Antibiotic selection'</a>.) </p><p/><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span></p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Hospital-acquired pneumonia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>P. aeruginosa</em> is a common cause of gram-negative hospital-acquired (nosocomial) pneumonia [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/1-6\" class=\"abstract_t\">1-6</a>]. This was illustrated in a prospective series of 556 patients in which <em>P. aeruginosa</em> was the most common gram-negative pathogen implicated in both hospital-acquired and ventilator-associated pneumonia [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/1\" class=\"abstract_t\">1</a>]. In a large multicenter survey of gram-negative aerobic bacteria isolated from patients in intensive care units (ICUs) in the US, <em>P. aeruginosa</em> was the most commonly isolated gram-negative aerobic bacterium (23 percent) and was the most common bacterium recurrently isolated from the respiratory tract (32 percent) [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/7\" class=\"abstract_t\">7</a>]. Hospital-acquired pneumonia can occur via aspiration of endogenous oral flora or via aspiration of organisms from contamination of ventilator tubing or other health care devices [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/8,9\" class=\"abstract_t\">8,9</a>]. Pulmonary infections due to <em>P. aeruginosa</em> may also arise hematogenously [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/10\" class=\"abstract_t\">10</a>]. <em>P. aeruginosa</em> is also an important cause of nosocomial tracheobronchitis [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/2\" class=\"abstract_t\">2</a>]. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-microbiology-and-diagnosis-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults&quot;</a>.)</p><p>Several risk factors for hospital-acquired pneumonia due to <em>P. aeruginosa</em> have been identified. In one study, a higher probability of <em>P. aeruginosa</em> pneumonia was associated with increased age, length of mechanical ventilation, antibiotics at admission, transfer from a medical unit or ICU, and admission in a ward with higher incidence of patients with <em>P. aeruginosa</em> infections [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/11\" class=\"abstract_t\">11</a>]. A lower probability of <em>P. aeruginosa</em> was associated with trauma and admission in a ward with high patient turnover.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Community-acquired pneumonia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although community-acquired <em>P. aeruginosa</em> pneumonia is occasionally reported in otherwise healthy hosts [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/12\" class=\"abstract_t\">12</a>], most patients have an identifiable risk factor for disease. Community-acquired <em>P. aeruginosa</em> pneumonia occurs mainly in individuals who have [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/13-15\" class=\"abstract_t\">13-15</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A compromised immune system (eg, HIV-infected patients, solid organ or hematopoietic cell transplant recipients, neutropenic hosts, and those on immunosuppressive or immunomodulatory agents such as TNF-alfa inhibitors)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recent prior antibiotic use</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Structural lung abnormalities such as cystic fibrosis or bronchiectasis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Repeated exacerbations of chronic obstructive pulmonary disease requiring frequent glucocorticoid <span class=\"nowrap\">and/or</span> antibiotic use</p><p/><p>As an example, <em>P. aeruginosa</em> causes 5 to 7 percent of cases of community-acquired pneumonia in HIV-infected patients [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/16,17\" class=\"abstract_t\">16,17</a>]. Additional risk factors for community-acquired pneumonia due to <em>P. aeruginosa</em> include cirrhosis [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/18\" class=\"abstract_t\">18</a>], history of recent hospitalization [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/14\" class=\"abstract_t\">14</a>], intubation [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/19\" class=\"abstract_t\">19</a>], or enteral tube feeding [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/20\" class=\"abstract_t\">20</a>]. In one study, <em>P. aeruginosa</em> pneumonia was responsible for 39 out of 559 cases of community-acquired pneumonia; previous hospital admission and pulmonary comorbidity were predictive of the occurrence of this infection [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/14\" class=\"abstract_t\">14</a>].</p><p>Person-to-person transmission of <em>P. aeruginosa</em> in the community is rare, but has been reported in a few isolated instances. As an example, household spread was documented when a daughter passed a <em>P. aeruginosa</em> strain to her mother, causing cavitary pneumonia and lung abscess; the two isolates were confirmed to be identical using pulsed-field gel electrophoresis [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/21\" class=\"abstract_t\">21</a>].</p><p>Other rare risks for <em>P. aeruginosa</em> include environmental exposures. As an example, one report described an isolated case of necrotizing <em>P. aeruginosa</em> pneumonia in an immunocompetent patient that was attributed to contact with a contaminated hot tub filter. This case highlights the importance of following the United States Centers for Disease Control and Prevention (CDC) guidelines for hot tub maintenance to prevent <em>Pseudomonas</em> overgrowth [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/22\" class=\"abstract_t\">22</a>].</p><p class=\"headingAnchor\" id=\"H1410424\"><span class=\"h2\">Equipment-related outbreaks</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Outbreaks of <em>P. aeruginosa</em> infection linked to contaminated health care equipment such as endoscopes have been occasionally reported [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/23-25\" class=\"abstract_t\">23-25</a>].</p><p>Bronchoscope contamination has been linked to defective design, bronchoscope damage, and inadequate disinfection [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/26\" class=\"abstract_t\">26</a>]. One outbreak related to defective bronchoscopes led to 32 cases of <em>P. aeruginosa</em> infections and three deaths prior to a voluntary recall of the endoscopes by the manufacturer [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/24\" class=\"abstract_t\">24</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">CLINICAL FEATURES</span></p><p class=\"headingAnchor\" id=\"H1410603\"><span class=\"h2\">Signs and symptoms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Signs and symptoms of pneumonia caused by <em>P. aeruginosa</em> are similar to those caused by other pyogenic bacteria or Legionella, and no features can reliably distinguish infection with <em>P. aeruginosa</em> specifically. Acute <em>P. aeruginosa</em> pneumonia is usually characterized by cough productive of purulent sputum, dyspnea, fever, chills, confusion, and severe systemic toxicity. Patients with ventilator-associated <em>P. aeruginosa</em> pneumonia may also present with increased tracheobronchial secretions and decreased ventilator performance, which can develop suddenly or gradually.</p><p>Although <em>P. aeruginosa</em> is typically associated with severe pneumonia, it is not a distinguishing feature. In a study of 343 patients with hospital-acquired pneumonia, the severity of illness was not associated with or predictive of microbial etiology [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/27\" class=\"abstract_t\">27</a>].</p><p>The general clinical features of community- and hospital-acquired pneumonia are discussed elsewhere. (See <a href=\"topic.htm?path=diagnostic-approach-to-community-acquired-pneumonia-in-adults#H2\" class=\"medical medical_review\">&quot;Diagnostic approach to community-acquired pneumonia in adults&quot;, section on 'Clinical evaluation'</a> and <a href=\"topic.htm?path=epidemiology-pathogenesis-microbiology-and-diagnosis-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults#H11\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults&quot;, section on 'Diagnosis'</a> and <a href=\"topic.htm?path=clinical-presentation-and-diagnostic-evaluation-of-ventilator-associated-pneumonia#H2632276373\" class=\"medical medical_review\">&quot;Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia&quot;, section on 'When to suspect ventilator-associated pneumonia'</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Radiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Radiographic findings are variable and no single finding is predictive or characteristic of <em>P. aeruginosa</em> pneumonia. Diffuse bilateral infiltrates, with or without pleural effusion, may be present. Many patients have multifocal airspace consolidation. Other radiographic features include nodular infiltrates, tree-in-bud opacities, and necrosis [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/28\" class=\"abstract_t\">28</a>]. Occasionally, areas of radiolucency suggestive of cavitary disease may be present. Classic lobar consolidation is uncommon.</p><p>When <em>P. aeruginosa</em> pneumonia arises from hematogenous spread of the organism, early radiographic findings may include pulmonary congestion and interstitial edema. However, diffuse interstitial and alveolar infiltrates often develop 24 to 48 hours later in such patients. Large hemorrhagic nodules with central necrosis or cavities may rarely occur later in the course.</p><p>Radiographic findings in certain hosts may also have particular characteristics. As an example, in a small study of 16 HIV-infected patients with <em>P. aeruginosa</em> pneumonia, of whom the majority had low CD4 cell counts, 11 presented with or subsequently developed cavitary infiltrates [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/29\" class=\"abstract_t\">29</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Pathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Histopathologic changes in patients with pneumonia due to <em>P. aeruginosa</em> typically include microabscesses with focal hemorrhage and necrosis of the alveolar septae without evidence of bacterial invasion of vessel walls or vascular necrosis. Pathologic changes in patients with pneumonia due to hematogenous spread usually include intra-alveolar hemorrhage and necrosis around pulmonary vessels. Small (2 to 15 mm), firm, yellow-brown necrotic nodules with dark red hemorrhagic parenchyma may also be present along with liquefactive necrosis or bacterial invasion of the alveolar cell walls.</p><p>One autopsy study of eight infants with <em>P. aeruginosa</em> pneumonia revealed two distinct histopathological patterns. Seven cases demonstrated evidence of a distinctive paucicellular coagulative confluent bronchopneumonia with perivascular bacillary infiltration. These changes occurred in immunocompromised patients with sepsis and rapid deterioration. The eighth case, a patient with an unusually protracted clinical course, had pathologic changes typical of bacterial pneumonia without evidence of perivascular organisms [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/30\" class=\"abstract_t\">30</a>].</p><p class=\"headingAnchor\" id=\"H1410697\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of <em>P. aeruginosa</em> pneumonia is made following the growth of <em>P. aeruginosa</em> on culture of expectorated sputum, bronchoscopically obtained samples, or other respiratory specimens in a patient with clinical and radiographic findings consistent with pneumonia. The diagnostic evaluation for pneumonia is discussed in detail elsewhere. (See <a href=\"topic.htm?path=diagnostic-approach-to-community-acquired-pneumonia-in-adults\" class=\"medical medical_review\">&quot;Diagnostic approach to community-acquired pneumonia in adults&quot;</a> and <a href=\"topic.htm?path=epidemiology-pathogenesis-microbiology-and-diagnosis-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults#H11\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults&quot;, section on 'Diagnosis'</a> and <a href=\"topic.htm?path=clinical-presentation-and-diagnostic-evaluation-of-ventilator-associated-pneumonia#H2756495\" class=\"medical medical_review\">&quot;Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia&quot;, section on 'Diagnostic evaluation'</a>.)</p><p>In some cases, particularly in the settings of intubation or chronic bronchiectasis, which can be associated with chronic growth of <em>P. aeruginosa</em> in the airways, the distinction between respiratory infection and colonization with <em>P. aeruginosa</em> may be difficult to make. Changes in clinical status such as new fever, new leukocytosis, new abnormality on chest imaging, and worsened respiratory status are suggestive of pneumonia in patients chronically colonized with <em>P. aeruginosa</em>. The use of quantitative cultures on sputum specimens from ventilated patients may also be helpful in distinguishing between infection and colonization [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/31\" class=\"abstract_t\">31</a>], but these techniques are not widely available and their use in clinical practice is uncommon. (See <a href=\"topic.htm?path=clinical-presentation-and-diagnostic-evaluation-of-ventilator-associated-pneumonia#H2756495\" class=\"medical medical_review\">&quot;Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia&quot;, section on 'Diagnostic evaluation'</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">MANAGEMENT</span></p><p class=\"headingAnchor\" id=\"H1410895\"><span class=\"h2\">Empiric antimicrobial therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Until antimicrobial susceptibility results are available, we initially treat known or suspected cases of <em>P. aeruginosa</em> pneumonia with a single antimicrobial agent, unless the patient has sepsis or risk factors for a drug resistant infection, in which case we use two antibiotics from different classes to which the isolate is likely to be susceptible (<a href=\"image.htm?imageKey=ID%2F91115\" class=\"graphic graphic_table graphicRef91115 \">table 1</a>).</p><p>Specifically, we agree with the guidelines from the Infectious Diseases Society of America and the American Thoracic Society on the empiric management of community-acquired and hospital-acquired pneumonia that recommend the following antimicrobial combinations for patients who have risk factors for both <em>P. aeruginosa</em> infection as well as drug resistance [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/13,32\" class=\"abstract_t\">13,32</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An antipseudomonal beta-lactam PLUS an antipseudomonal quinolone</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An antipseudomonal beta-lactam PLUS an aminoglycoside</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An antipseudomonal quinolone PLUS an aminoglycoside</p><p/><p>Antipseudomonal beta-lactams include <a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-drug-information\" class=\"drug drug_general\">piperacillin-tazobactam</a>, <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">ceftazidime</a>, <a href=\"topic.htm?path=cefepime-drug-information\" class=\"drug drug_general\">cefepime</a>, <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a>, <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a>, and <a href=\"topic.htm?path=doripenem-drug-information\" class=\"drug drug_general\">doripenem</a>. <a href=\"topic.htm?path=aztreonam-drug-information\" class=\"drug drug_general\">Aztreonam</a> may be substituted for one of these in the setting of penicillin allergy. Antipseudomonal quinolones include <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> and <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> (750 mg dose).</p><p>Antimicrobial selection should also include consideration of local antimicrobial resistance patterns. Additional details, including dosing, on antibiotic regimens for the treatment of <em>P. aeruginosa</em> infections are found elsewhere (<a href=\"image.htm?imageKey=ID%2F91115\" class=\"graphic graphic_table graphicRef91115 \">table 1</a>). (See <a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections#H5\" class=\"medical medical_review\">&quot;Principles of antimicrobial therapy of Pseudomonas aeruginosa infections&quot;, section on 'Intravenous antibiotics'</a>.)</p><p>Risk factors for <em>P. aeruginosa</em> among patients presenting with hospital- or community-acquired pneumonia are discussed elsewhere, as are risk factors for antimicrobial resistance. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above and <a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections#H6674788\" class=\"medical medical_review\">&quot;Principles of antimicrobial therapy of Pseudomonas aeruginosa infections&quot;, section on 'Antimicrobial resistance'</a>.)</p><p>The evidence for combination versus monotherapy is also discussed separately. (See <a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections#H6675458\" class=\"medical medical_review\">&quot;Principles of antimicrobial therapy of Pseudomonas aeruginosa infections&quot;, section on 'Combination antimicrobial therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Directed antimicrobial therapy</span></p><p class=\"headingAnchor\" id=\"H1410985\"><span class=\"h3\">Regimen choice</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest streamlining empiric combination therapy to a single active antibiotic once susceptibility results are available (<a href=\"image.htm?imageKey=ID%2F91115\" class=\"graphic graphic_table graphicRef91115 \">table 1</a>). We typically use a beta-lactam, reserving carbapenems for treating polymicrobial infections or organisms resistant to other agents. In general, aminoglycosides should <strong>not</strong> be used as monotherapy for pneumonia because they perform poorly in an acidic environment.</p><p>Although some experts continue a combination regimen as directed therapy in order to minimize the emergence of antimicrobial resistance, there is little clinical evidence that clearly demonstrates a benefit to directed combination therapy. In a multicenter study of 183 patients with ventilator-associated pneumonia due to <em>P. aeruginosa</em>, use of combination therapy or monotherapy tailored to susceptibility results did not influence mortality, length of stay, recurrent infection rate, or development of resistance [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/33\" class=\"abstract_t\">33</a>]. (See <a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections#H6675458\" class=\"medical medical_review\">&quot;Principles of antimicrobial therapy of Pseudomonas aeruginosa infections&quot;, section on 'Combination antimicrobial therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H1410972\"><span class=\"h3\">Duration of therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal duration of antimicrobial therapy for <em>P. aeruginosa</em> pneumonia is uncertain. We individualize the duration based on the underlying comorbidities and condition of the patient, the initial response to therapy, and the susceptibility of the infecting isolate. Patients who have no significant comorbidities, defervesce and improve clinically within the first week of therapy, and have infection with a susceptible <em>P. aeruginosa</em> isolate can be treated with regimens as short as 7 to 10 days. However, longer treatment durations (eg, from 10 to 21 days) may be warranted for patients with serious underlying conditions (eg, neutropenia), concurrent blood stream infection, a poor or slow response to therapy, <span class=\"nowrap\">and/or</span> a partially susceptible or multidrug-resistant strain. If the isolate is susceptible to fluoroquinolones and there are no concerns about gastrointestinal absorption of oral medications, the patient can transition to oral <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> or <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> to complete the course.</p><p>Support for a relatively abbreviated course of antibiotics comes from several trials on treatment of ventilator-associated pneumonia, in which short (seven- to eight-day) courses of antibiotics resulted in similar clinical cure and mortality rates and lower rates of recurrence with multidrug-resistant organisms compared with longer (10- to 15-day) courses [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/34,35\" class=\"abstract_t\">34,35</a>]. However, in some studies, the recurrence rate for pneumonias caused by nonfermenting gram-negative bacilli (such as <em>P. aeruginosa</em>) was higher with short courses. Thus, while a short course may be appropriate for some patients with <em>P. aeruginosa</em> pneumonia, we favor a more conservative approach with a longer course of therapy in patients who may have an especially high mortality because of comorbidities or clinical course.</p><p>The airway may remain colonized with <em>P. aeruginosa</em> even in the setting of clinical response. Symptomatic improvement is a more important indicator than organism eradication for decisions regarding timing of antibiotic discontinuation.</p><p class=\"headingAnchor\" id=\"H1210512861\"><span class=\"h2\">Inhaled antibiotics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We do not routinely use inhaled antibiotics for the treatment of <em>P. aeruginosa</em> pneumonia, although they may be effective as an adjunct to intravenous therapy in cases of infection due to multidrug-resistant strains. </p><p>Specifically, inhaled polymyxins have been used successfully in the management of multidrug-resistant <em>P. aeruginosa</em> pneumonia failing to improve on IV therapy [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/36-39\" class=\"abstract_t\">36-39</a>]. In a retrospective study from Italy of patients with ventilator-associated pneumonia (VAP) due to gram-negative organisms sensitive only to <a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">colistin</a>, clinical cure rates were higher (69 versus 55 percent, p = 0.03) and duration of post-VAP mechanical ventilation shorter (median 8 versus 12 days) among 104 patients (24 with <em>P. aeruginosa</em>) who received nebulized and intravenous colistin compared with 104 matched patients (28 with <em>P. aeruginosa</em>) who received only intravenous colistin [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/39\" class=\"abstract_t\">39</a>]. Nebulized colistin in treatment of pneumonia due to multidrug-resistant <em>Acinetobacter baumannii</em> and <em>P. aeruginosa</em> was evaluated in a retrospective study of 21 patients in Singapore [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/37\" class=\"abstract_t\">37</a>]. Overall clinical and microbiological response rates were 57 and 86 percent, respectively. Most patients received 1 million units (approximately 80 mg) of colistin twice daily. There was no significant change in renal function or observed neurotoxicity. (See <a href=\"topic.htm?path=polymyxins-an-overview\" class=\"medical medical_review\">&quot;Polymyxins: An overview&quot;</a>.)</p><p><a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">Colistin</a> is approved by the FDA only for intravenous or intramuscular use; it is not approved as a liquid to be inhaled via nebulizer. When the drug is mixed into a liquid form, the product can break down into other chemicals that can damage lung tissue [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/40\" class=\"abstract_t\">40</a>]. Instructions regarding preparation of nebulized colistin are discussed separately. (See <a href=\"topic.htm?path=polymyxins-an-overview\" class=\"medical medical_review\">&quot;Polymyxins: An overview&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H1410951\"><span class=\"h2\">Strategies for drug resistant isolates</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Drug-resistant <em>P. aeruginosa</em> infections should be managed with the assistance of an expert in the treatment of multidrug-resistant pathogens. Strategies for such infections include the use of inhaled antibiotics, alternative intravenous agents, and certain combination regimens. These are discussed elsewhere. (See <a href=\"#H1210512861\" class=\"local\">'Inhaled antibiotics'</a> above and <a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections#H6675731\" class=\"medical medical_review\">&quot;Principles of antimicrobial therapy of Pseudomonas aeruginosa infections&quot;, section on 'Strategies for multidrug-resistant organisms'</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">OUTCOME AND PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>P. aeruginosa</em> pneumonia is associated with high in-hospital mortality rates and prolonged lengths of stay [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/4,26\" class=\"abstract_t\">4,26</a>]. Injury to the alveolar epithelium allows the release of proinflammatory mediators into the circulation that are primarily responsible for septic shock [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/41\" class=\"abstract_t\">41</a>]. (See <a href=\"topic.htm?path=sepsis-syndromes-in-adults-epidemiology-definitions-clinical-presentation-diagnosis-and-prognosis\" class=\"medical medical_review\">&quot;Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis&quot;</a>.)</p><p><em>P. aeruginosa</em> pneumonia accompanied by <em>P. aeruginosa</em> bacteremia is associated with a particularly poor prognosis, with death occurring three to four days after the first signs of infection in the majority of cases.</p><p>Other factors significantly associated with a poor prognosis include [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/4,42-44\" class=\"abstract_t\">4,42-44</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Advanced age</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serious underlying disease</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Septic shock</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acute respiratory distress syndrome</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Previous surgery and other co-morbidities, such as diabetes mellitus</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inadequate initial antibiotic therapy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Use of broad-spectrum antibiotics in previous six months</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multidrug-resistant organisms</p><p/><p>As an example, in a study of 110 ICU patients with culture confirmed <em>P. aeruginosa</em> pneumonia, inadequate initial antibiotic therapy, diabetes mellitus, disease severity (high Simplified Acute Physiology Score [SAPS] II), and older age were independently associated with ICU mortality [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/44\" class=\"abstract_t\">44</a>]. Among survivors, inappropriate initial antibiotic therapy and infection with multidrug-resistant <em>P. aeruginosa</em> infection were each associated with longer post-pneumonia mechanical ventilation time.</p><p class=\"headingAnchor\" id=\"H371766596\"><span class=\"h1\">PSEUDOMONAS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Isolation of <em>P. aeruginosa</em> from sputum samples of adult patients with COPD is associated with advanced pulmonary disease [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/45\" class=\"abstract_t\">45</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one cross-sectional study, patients with a predicted FEV1 of less than 50 percent were more likely to have H. influenzae or <em>P. aeruginosa </em>isolated from sputum during exacerbations than patients with less severe impairment of pulmonary function [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/46\" class=\"abstract_t\">46</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Another study demonstrated that in patients who had FEV1 less than 35 percent the predicted value, Enterobacteriaceae and <em>Pseudomonas</em> species were the predominant isolated bacteria from sputum [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/47\" class=\"abstract_t\">47</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a separate study, the presence of enteric gram-negative bacilli and <em>P. aeruginosa</em> in the sputum of patients during exacerbations could be predicted by severe airflow obstruction [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/48\" class=\"abstract_t\">48</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Furthermore, exacerbations in the presence of <em>P. aeruginosa</em> in the sputum are linked to respiratory failure and the need for mechanical ventilation. These interpretations may suggest that <em>P. aeruginosa</em> is a more frequent cause of infection as COPD progresses.</p><p/><p>There exists a subset of patients with COPD who become chronically colonized with <em>P. aeruginosa</em>, but whether such patients benefit from antimicrobial therapy is still unclear.</p><p class=\"headingAnchor\" id=\"H469449585\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Pseudomonas aeruginosa</em> is one of the most important and most commonly considered pathogens in the differential diagnosis of gram-negative infections. <em>P. aeruginosa</em> has the capacity to cause severe or fatal nosocomial infections, especially in immunocompromised hosts. Furthermore, it is often resistant to commonly used antibiotics. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>P. aeruginosa</em> is a common cause of gram-negative hospital-acquired pneumonia, which can occur via aspiration of endogenous oral flora, via aspiration of organisms from contaminated ventilator tubing or other health care devices, or through hematogenous spread. (See <a href=\"#H3\" class=\"local\">'Hospital-acquired pneumonia'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Community-acquired <em>P. aeruginosa</em> pneumonia occurs mainly in immunocompromised patients (eg, HIV-infected patients, solid organ or stem cell transplant recipients, or neutropenic hosts), those with recent prior antibiotic use, and those with structural lung abnormalities such as cystic fibrosis, bronchiectasis, or repeated exacerbations of chronic obstructive pulmonary disease requiring frequent glucocorticoid <span class=\"nowrap\">and/or</span> antibiotic use. (See <a href=\"#H5\" class=\"local\">'Community-acquired pneumonia'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>P. aeruginosa</em> pneumonia is usually characterized by cough productive of purulent sputum, dyspnea, fever, chills, confusion, and severe systemic toxicity. None of these manifestations firmly distinguish this infection from pneumonia caused by other pyogenic organisms or Legionella. Radiographic findings are variable and no single finding is predictive or characteristic of <em>P. aeruginosa</em> pneumonia. (See <a href=\"#H6\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of <em>P. aeruginosa</em> pneumonia is made following the growth of <em>P. aeruginosa</em> on culture of expectorated sputum, bronchoscopically-obtained samples, or other respiratory specimens in a patient with clinical and radiographic findings consistent with pneumonia. (See <a href=\"#H1410697\" class=\"local\">'Diagnosis'</a> above and <a href=\"topic.htm?path=epidemiology-pathogenesis-microbiology-and-diagnosis-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Until antimicrobial susceptibility results are available, suspected cases of <em>P. aeruginosa</em> pneumonia can be empirically treated with a single antimicrobial agent, unless the patient has sepsis or risk factors for a drug resistant infection, in which case we use two antibiotics from different classes to which the isolate is likely to be susceptible (<a href=\"image.htm?imageKey=ID%2F91115\" class=\"graphic graphic_table graphicRef91115 \">table 1</a>). The rationale for combination versus monotherapy is discussed elsewhere. (See <a href=\"#H1410895\" class=\"local\">'Empiric antimicrobial therapy'</a> above and <a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections#H6675458\" class=\"medical medical_review\">&quot;Principles of antimicrobial therapy of Pseudomonas aeruginosa infections&quot;, section on 'Combination antimicrobial therapy'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Once susceptibility testing results are available, we suggest use of a single active antibiotic for directed therapy of susceptible infections instead of combination therapy (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). Patients who have no significant comorbidities, defervesce and improve clinically within the first week of therapy, and have infection with a susceptible <em>P. aeruginosa</em> isolate can be treated with regimens as short as 7 to 10 days. Longer treatment durations (eg, from 10 to 21 days) may be warranted for other patients. (See <a href=\"#H11\" class=\"local\">'Directed antimicrobial therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multidrug-resistant <em>P. aeruginosa</em> infections should be managed with the assistance of an expert in the treatment of such infections. Alternative agents such as <a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">colistin</a> may be necessary. Other possible strategies for resistant infections include the use of inhaled antibiotics, combination regimens, and alternative dosing strategies. (See <a href=\"#H1210512861\" class=\"local\">'Inhaled antibiotics'</a> above and <a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections#H6675731\" class=\"medical medical_review\">&quot;Principles of antimicrobial therapy of Pseudomonas aeruginosa infections&quot;, section on 'Strategies for multidrug-resistant organisms'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>P. aeruginosa</em> pneumonia is associated with high in-hospital mortality rates and prolonged lengths of stay. (See <a href=\"#H13\" class=\"local\">'Outcome and prognosis'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/1\" class=\"nounderline abstract_t\">Weber DJ, Rutala WA, Sickbert-Bennett EE, et al. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol 2007; 28:825.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/2\" class=\"nounderline abstract_t\">Nseir S, Di Pompeo C, Pronnier P, et al. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome. Eur Respir J 2002; 20:1483.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/3\" class=\"nounderline abstract_t\">Rello J, Quintana E, Ausina V, et al. Incidence, etiology, and outcome of nosocomial pneumonia in mechanically ventilated patients. Chest 1991; 100:439.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/4\" class=\"nounderline abstract_t\">Crabtree TD, Gleason TG, Pruett TL, Sawyer RG. Trends in nosocomial pneumonia in surgical patients as we approach the 21st century: a prospective analysis. Am Surg 1999; 65:706.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/5\" class=\"nounderline abstract_t\">Gales AC, Sader H HS, Jones RN. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2002; 44:301.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/6\" class=\"nounderline abstract_t\">Rello J, Borgatta B, Lisboa T. Risk factors for Pseudomonas aeruginosa pneumonia in the early twenty-first century. Intensive Care Med 2013; 39:2204.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/7\" class=\"nounderline abstract_t\">Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289:885.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/8\" class=\"nounderline abstract_t\">Agodi A, Barchitta M, Cipresso R, et al. Pseudomonas aeruginosa carriage, colonization, and infection in ICU patients. Intensive Care Med 2007; 33:1155.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/9\" class=\"nounderline abstract_t\">Vall&eacute;s J, Mariscal D, Cort&eacute;s P, et al. Patterns of colonization by Pseudomonas aeruginosa in intubated patients: a 3-year prospective study of 1,607 isolates using pulsed-field gel electrophoresis with implications for prevention of ventilator-associated pneumonia. Intensive Care Med 2004; 30:1768.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/10\" class=\"nounderline abstract_t\">Kumar PD, Ravakhah K, West BC. Disseminated Pseudomonas aeruginosa and necrotizing pneumonia with complete recovery. South Med J 2001; 94:229.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/11\" class=\"nounderline abstract_t\">Venier AG, Gruson D, Lavigne T, et al. Identifying new risk factors for Pseudomonas aeruginosa pneumonia in intensive care units: experience of the French national surveillance, REA-RAISIN. J Hosp Infect 2011; 79:44.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/12\" class=\"nounderline abstract_t\">Henderson A, Kelly W, Wright M. Fulminant primary Pseudomonas aeruginosa pneumonia and septicaemia in previously well adults. Intensive Care Med 1992; 18:430.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/13\" class=\"nounderline abstract_t\">Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/14\" class=\"nounderline abstract_t\">Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162:1849.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/15\" class=\"nounderline abstract_t\">Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007; 26:411.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/16\" class=\"nounderline abstract_t\">L&oacute;pez-Palomo C, Mart&iacute;n-Zamorano M, Ben&iacute;tez E, et al. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol 2004; 72:517.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/17\" class=\"nounderline abstract_t\">Madeddu G, Porqueddu EM, Cambosu F, et al. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era. Infection 2008; 36:231.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/18\" class=\"nounderline abstract_t\">Viasus D, Garcia-Vidal C, Castellote J, et al. Community-acquired pneumonia in patients with liver cirrhosis: clinical features, outcomes, and usefulness of severity scores. Medicine (Baltimore) 2011; 90:110.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/19\" class=\"nounderline abstract_t\">Rello J, Rodriguez A, Torres A, et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006; 27:1210.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/20\" class=\"nounderline abstract_t\">von Baum H, Welte T, Marre R, et al. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors. Eur Respir J 2010; 35:598.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/21\" class=\"nounderline abstract_t\">Patel P, Whittier S, Frank E. Person-to-person transmission of Pseudomonas pneumonia in the community: documentation by pulsed-field electrophoresis. South Med J 2002; 95:653.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/22\" class=\"nounderline abstract_t\">Crnich CJ, Gordon B, Andes D. Hot tub-associated necrotizing pneumonia due to Pseudomonas aeruginosa. Clin Infect Dis 2003; 36:e55.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/23\" class=\"nounderline abstract_t\">Kirschke DL, Jones TF, Craig AS, et al. Pseudomonas aeruginosa and Serratia marcescens contamination associated with a manufacturing defect in bronchoscopes. N Engl J Med 2003; 348:214.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/24\" class=\"nounderline abstract_t\">Srinivasan A, Wolfenden LL, Song X, et al. An outbreak of Pseudomonas aeruginosa infections associated with flexible bronchoscopes. N Engl J Med 2003; 348:221.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/25\" class=\"nounderline abstract_t\">Engelhart S, Krizek L, Glasmacher A, et al. Pseudomonas aeruginosa outbreak in a haematology-oncology unit associated with contaminated surface cleaning equipment. J Hosp Infect 2002; 52:93.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/26\" class=\"nounderline abstract_t\">Fujitani S, Sun HY, Yu VL, Weingarten JA. Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest 2011; 139:909.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/27\" class=\"nounderline abstract_t\">Di Pasquale M, Ferrer M, Esperatti M, et al. Assessment of severity of ICU-acquired pneumonia and association with etiology. Crit Care Med 2014; 42:303.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/28\" class=\"nounderline abstract_t\">Shah RM, Wechsler R, Salazar AM, Spirn PW. Spectrum of CT findings in nosocomial Pseudomonas aeruginosa pneumonia. J Thorac Imaging 2002; 17:53.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/29\" class=\"nounderline abstract_t\">Schuster MG, Norris AH. Community-acquired Pseudomonas aeruginosa pneumonia in patients with HIV infection. AIDS 1994; 8:1437.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/30\" class=\"nounderline abstract_t\">Bonifacio SL, Kitterman JA, Ursell PC. Pseudomonas pneumonia in infants: an autopsy study. Hum Pathol 2003; 34:929.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/31\" class=\"nounderline abstract_t\">Deschaght P, Schelstraete P, Van Simaey L, et al. Is the improvement of CF patients, hospitalized for pulmonary exacerbation, correlated to a decrease in bacterial load? PLoS One 2013; 8:e79010.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/32\" class=\"nounderline abstract_t\">American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/33\" class=\"nounderline abstract_t\">Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007; 35:1888.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/34\" class=\"nounderline abstract_t\">Pugh R, Grant C, Cooke RP, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2015; :CD007577.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/35\" class=\"nounderline abstract_t\">Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/36\" class=\"nounderline abstract_t\">Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis 2007; 58:235.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/37\" class=\"nounderline abstract_t\">Kwa AL, Loh C, Low JG, et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005; 41:754.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/38\" class=\"nounderline abstract_t\">Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000; 162:328.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/39\" class=\"nounderline abstract_t\">Tumbarello M, De Pascale G, Trecarichi EM, et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest 2013; 144:1768.</a></li><li class=\"breakAll\">www.fda.gov/cder/drug/advisory/colistimethate.htm (Accessed on July 30, 2007).</li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/41\" class=\"nounderline abstract_t\">Kurahashi K, Kajikawa O, Sawa T, et al. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest 1999; 104:743.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/42\" class=\"nounderline abstract_t\">Mart&iacute;nez B, G&oacute;mez J, G&oacute;mez Vargas J, et al. [Risk factors and prognosis of nosocomial pneumonia due to gram-negative bacteria in a general hospital]. Rev Esp Quimioter 2000; 13:187.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/43\" class=\"nounderline abstract_t\">Wang CY, Jerng JS, Chen KY, et al. Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes. Clin Microbiol Infect 2006; 12:63.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/44\" class=\"nounderline abstract_t\">Tumbarello M, De Pascale G, Trecarichi EM, et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med 2013; 39:682.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/45\" class=\"nounderline abstract_t\">Murphy TF. Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease. Curr Opin Pulm Med 2009; 15:138.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/46\" class=\"nounderline abstract_t\">Miravitlles M, Espinosa C, Fern&aacute;ndez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116:40.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/47\" class=\"nounderline abstract_t\">Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113:1542.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-pneumonia/abstract/48\" class=\"nounderline abstract_t\">Lode H, Allewelt M, Balk S, et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection 2007; 35:143.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3133 Version 21.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H469449585\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Hospital-acquired pneumonia</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Community-acquired pneumonia</a></li><li><a href=\"#H1410424\" id=\"outline-link-H1410424\">Equipment-related outbreaks</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">CLINICAL FEATURES</a><ul><li><a href=\"#H1410603\" id=\"outline-link-H1410603\">Signs and symptoms</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Radiology</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Pathology</a></li></ul></li><li><a href=\"#H1410697\" id=\"outline-link-H1410697\">DIAGNOSIS</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">MANAGEMENT</a><ul><li><a href=\"#H1410895\" id=\"outline-link-H1410895\">Empiric antimicrobial therapy</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Directed antimicrobial therapy</a><ul><li><a href=\"#H1410985\" id=\"outline-link-H1410985\">- Regimen choice</a></li><li><a href=\"#H1410972\" id=\"outline-link-H1410972\">- Duration of therapy</a></li></ul></li><li><a href=\"#H1210512861\" id=\"outline-link-H1210512861\">Inhaled antibiotics</a></li><li><a href=\"#H1410951\" id=\"outline-link-H1410951\">Strategies for drug resistant isolates</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">OUTCOME AND PROGNOSIS</a></li><li><a href=\"#H371766596\" id=\"outline-link-H371766596\">PSEUDOMONAS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE</a></li><li><a href=\"#H469449585\" id=\"outline-link-H469449585\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/3133|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/91115\" class=\"graphic graphic_table\">- Antibiotics used for the treatment of P. aeruginosa infections</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-diagnostic-evaluation-of-ventilator-associated-pneumonia\" class=\"medical medical_review\">Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cystic-fibrosis-antibiotic-therapy-for-chronic-pulmonary-infection\" class=\"medical medical_review\">Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cystic-fibrosis-treatment-of-acute-pulmonary-exacerbations\" class=\"medical medical_review\">Cystic fibrosis: Treatment of acute pulmonary exacerbations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-approach-to-community-acquired-pneumonia-in-adults\" class=\"medical medical_review\">Diagnostic approach to community-acquired pneumonia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection\" class=\"medical medical_review\">Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-pathogenesis-microbiology-and-diagnosis-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults\" class=\"medical medical_review\">Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=polymyxins-an-overview\" class=\"medical medical_review\">Polymyxins: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections\" class=\"medical medical_review\">Principles of antimicrobial therapy of Pseudomonas aeruginosa infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pseudomonas-aeruginosa-bacteremia-and-endocarditis\" class=\"medical medical_review\">Pseudomonas aeruginosa bacteremia and endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pseudomonas-aeruginosa-infections-of-the-eye-ear-urinary-tract-gastrointestinal-tract-and-central-nervous-system\" class=\"medical medical_review\">Pseudomonas aeruginosa infections of the eye, ear, urinary tract, gastrointestinal tract, and central nervous system</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pseudomonas-aeruginosa-skin-and-soft-tissue-infections\" class=\"medical medical_review\">Pseudomonas aeruginosa skin and soft tissue infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sepsis-syndromes-in-adults-epidemiology-definitions-clinical-presentation-diagnosis-and-prognosis\" class=\"medical medical_review\">Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis</a></li></ul></div></div>","javascript":null}